QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.103.048702v1 306/1/116    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kinney, G. G. Articles by Conn, P. J. Search for Related Content PubMed PubMed Citation Articles by Kinney, G. G. Articles by Conn, P. J.

BEHAVIORAL PHARMACOLOGY

Metabotropic Glutamate Subtype 5 Receptors Modulate Locomotor Activity and Sensorimotor Gating in Rodents

Department of Neuroscience, Merck Research Laboratories, West Point, Pennsylvania (G.G.K., M.B., P.J.C.); and Behavioral Pharmacology, San Diego, California (U.C.C., L.M.H., D.R., L.J.B.)

Use-dependent N-methyl-D-aspartate receptor (NMDAR) antagonists produce behaviors in human volunteers that resemble schizophrenia and exacerbate those behaviors in schizophrenic patients, suggesting that hypofunction of NMDAR-mediated neuronal circuitry may be involved in the etiology of clinical schizophrenia. Activation of the metabotropic glutamate receptor subtype 5 (mGluR5) enhances NMDAR-mediated currents in vitro. Thus, activation of mGluR5 could potentiate hypofunctional NMDARs in neuronal circuitry relevant to schizophrenia. To further elucidate the role of mGluR5, the present study examined the effects of mGluR5 antagonist administration, with and without coadministration of the use-dependent NMDAR antagonist phencyclidine (PCP), on locomotor activity and prepulse inhibition (PPI) of the acoustic startle response in rodents. We further examined PPI in mGluR5 knockout mice. Finally, we examined PPI after administration of the mGluR5 agonist 2-chloro-5-hydroxyphenylglycine (CHPG) alone and in combination with amphetamine. The data indicate that the mGluR5 antagonist 2-methyl-6-(phenylethynyl)pyridine has no effect on locomotor activity or PPI by itself but does potentiate both PCP-induced locomotor activity and disruption of PPI. We further found that mGluR5 knockout mice display consistent deficits in PPI relative to their wild-type controls. Finally, the data indicate that CHPG has no effect on PPI by itself, but ameliorates amphetamine-induced disruption of PPI. Collectively, these data suggest that mGlu5 receptors play a modulatory role on rodent PPI and locomotor behaviors and are consistent with the hypothesis that mGlu5 agonist/potentiators may represent a novel approach for antipsychotic drug development.

Address correspondence to: Dr. Gene G. Kinney, Department of Neuroscience, Merck and Co., Inc., P.O. Box 4, WP46–300, West Point, PA 19486. E-mail: gene_kinney{at}merck.com

This article has been cited by other articles:

				F. Lallemand, R. J. Ward, and P. De Witte The Influence of Chronic Nicotine Administration on Behavioural and Neurochemical Parameters in Male and Female Rats after Repeated Binge Drinking Exposure Alcohol Alcohol., November 1, 2009; 44(6): 535 - 546. [Abstract] [Full Text] [PDF]

				A. Satow, G. Suzuki, S. Maehara, H. Hikichi, T. Murai, T. Murai, H. Kawagoe-Takaki, M. Hata, S. Ito, S. Ozaki, et al. Unique Antipsychotic Activities of the Selective Metabotropic Glutamate Receptor 1 Allosteric Antagonist 2-Cyclopropyl-5-[1-(2-fluoro-3-pyridinyl)-5-methyl-1H-1,2,3-triazol-4-yl]-2,3-dihydro-1H-isoindol-1-one J. Pharmacol. Exp. Ther., July 1, 2009; 330(1): 179 - 190. [Abstract] [Full Text] [PDF]

				C. H. Large Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs? J Psychopharmacol, May 1, 2007; 21(3): 283 - 301. [Abstract] [PDF]

				J. Cilia, P. Hatcher, C. Reavill, and D. N. C. Jones ({+/-}) Ketamine-induced prepulse inhibition deficits of an acoustic startle response in rats are not reversed by antipsychotics J Psychopharmacol, May 1, 2007; 21(3): 302 - 311. [Abstract] [PDF]

				X. Li, A. B. Need, M. Baez, and J. M. Witkin Metabotropic Glutamate 5 Receptor Antagonism Is Associated with Antidepressant-Like Effects in Mice J. Pharmacol. Exp. Ther., October 1, 2006; 319(1): 254 - 259. [Abstract] [Full Text] [PDF]

				H. Homayoun and B. Moghaddam Bursting of Prefrontal Cortex Neurons in Awake Rats is Regulated by Metabotropic Glutamate 5 (mGlu5) Receptors: Rate-dependent Influence and Interaction with NMDA Receptors Cereb Cortex, January 1, 2006; 16(1): 93 - 105. [Abstract] [Full Text] [PDF]

				Y. Zhang, A. L. Rodriguez, and P. J. Conn Allosteric Potentiators of Metabotropic Glutamate Receptor Subtype 5 Have Differential Effects on Different Signaling Pathways in Cortical Astrocytes J. Pharmacol. Exp. Ther., December 1, 2005; 315(3): 1212 - 1219. [Abstract] [Full Text] [PDF]

				M. S. Cowen, E. Djouma, and A. J. Lawrence The Metabotropic Glutamate 5 Receptor Antagonist 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-pyridine Reduces Ethanol Self-Administration in Multiple Strains of Alcohol-Preferring Rats and Regulates Olfactory Glutamatergic Systems J. Pharmacol. Exp. Ther., November 1, 2005; 315(2): 590 - 600. [Abstract] [Full Text] [PDF]

				G. G. Kinney, J. A. O'Brien, W. Lemaire, M. Burno, D. J. Bickel, M. K. Clements, T.-B. Chen, D. D. Wisnoski, C. W. Lindsley, P. R. Tiller, et al. A Novel Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Has in Vivo Activity and Antipsychotic-Like Effects in Rat Behavioral Models J. Pharmacol. Exp. Ther., April 1, 2005; 313(1): 199 - 206. [Abstract] [Full Text] [PDF]

				J. A. O'Brien, W. Lemaire, M. Wittmann, M. A. Jacobson, S. N. Ha, D. D. Wisnoski, C. W. Lindsley, H. J. Schaffhauser, B. Rowe, C. Sur, et al. A Novel Selective Allosteric Modulator Potentiates the Activity of Native Metabotropic Glutamate Receptor Subtype 5 in Rat Forebrain J. Pharmacol. Exp. Ther., May 1, 2004; 309(2): 568 - 577. [Abstract] [Full Text] [PDF]